Compound Reference

Thymosin Alpha-1

A thymic immunomodulatory peptide studied for TLR activation, T-cell regulation, and innate immune signaling in viral and oncology research models.

Thymic peptideC₁₂₉H₂₁₅N₃₃O₅₅Approx. 2 hours (subcutaneous, clinical data)
Innate Immune SignalingT-cell RegulationAntiviral ResearchDendritic Cell MaturationImmune Senescence

Overview

Thymosin Alpha-1 is a 28-amino acid peptide first isolated by Allan Goldstein and colleagues from thymosin fraction 5 of calf thymus tissue in the 1970s. It is now produced synthetically and is approved as a pharmaceutical product (Zadaxin) in multiple countries for treatment of chronic hepatitis B and C, and as an immunotherapy adjunct in cancer research contexts. It acts by activating Toll-like receptors (TLR2 and TLR9) on dendritic cells and macrophages, promoting innate immune recognition and antigen-presenting cell maturation, with downstream effects on cytotoxic T-cell and regulatory T-cell differentiation. Among peptide research compounds, it has one of the most extensive human clinical data profiles.

Quick Reference

Sequence
28 amino acids, N-terminally acetylated
Origin
Isolated from thymosin fraction 5 by Allan Goldstein, 1970s
Regulatory approval
Approved as Zadaxin in 30+ countries for hepatitis B/C
Primary mechanism
TLR2/TLR9 activation, dendritic cell maturation, T-cell modulation
Purity standard
>=98% by HPLC
Mechanism

How It Works

Thymosin Alpha-1 activates TLR2 and TLR9 on dendritic cells and macrophages, triggering innate immune signaling cascades that promote dendritic cell maturation, IL-12 production, and antigen presentation capacity. Downstream effects include enhanced cytotoxic T-cell (CD8+) differentiation and activity, and modulation of regulatory T-cell (Treg) populations, supporting both immune activation in hypo-immune states and immune balance in dysregulated contexts.

Research Highlights

Key findings from the published preclinical literature.

1

Hepatitis B and C Clinical Trials

Multiple randomized controlled trials have examined Thymosin Alpha-1 in chronic hepatitis B and C, documenting improvements in viral clearance and sustained virological response rates, supporting its approval as Zadaxin in over 30 countries.

2

Cancer Immunotherapy Adjunct Research

Studies have examined Thymosin Alpha-1 as an immunotherapy adjunct in lung cancer, melanoma, and hepatocellular carcinoma models, with documented improvements in immune response parameters and some survival data in combination trials.

3

Sepsis and Immune Dysfunction Models

Research in sepsis-associated immune dysfunction has documented Thymosin Alpha-1 effects on monocyte and T-cell function restoration in immunoparalysis states, with clinical trials examining its role in sepsis immune reconstitution.

4

Dendritic Cell Maturation Assays

In vitro dendritic cell maturation studies have documented Thymosin Alpha-1 induction of CD80, CD86, MHC-II, and IL-12 expression in human monocyte-derived dendritic cells, providing mechanistic support for its antigen presentation-enhancing properties.

Research Connections

Related research areas, stacks, and comparisons involving this compound.

Frequently Asked Questions

Thymosin Alpha-1 ships to researchers across the United States. Ordering information and local shipping details are available for California researchers, Texas researchers, Florida researchers, New York researchers, and all 50 states.

Source This Compound

Thymosin Alpha-1 is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply, same-day dispatch before 2 PM EST. For in-vitro research use only.

All compounds are strictly for in-vitro research use only and not intended for human consumption.